India
· Delayed Price · Currency is INR Jenburkt Pharmaceuticals Company Description
Jenburkt Pharmaceuticals Limited researches and develops, manufactures, and markets pharmaceutical and healthcare products in India.
It offers products in various therapeutic areas, such as pain management, analgesic and anti-pyretics, muscle relaxants, nutraceuticals, neuropathic pain, anti-arthritic, anti-infectives, antifungals, antiulcerants/antacids, aphrodisiacs, antimalarials, anthelmintics, cough and cold, and anti- diabetics, as well as consumer products.
The company offers its products under the Allerzine, CartiSafe Forte, Eberjen, ECOPROT, Frendacid, Fundu, Glajen-E, GLUCOTROL, HYBRITA, Jenflam, La-Viril, LUMA, Lubtriben, Metmin, Nervega-75, Nervijen P, Nervijen, NOCAL, Numox-625, OJEN, ORNEL, Oxicojen, PANTAZOLE, PIRITEXYL, POWERDOL, Powergesic, Rabera, Topcal-M, Trapidol-D, TREGA, TRIBEN, ZENGLOBIN, ZIX, Zix-MR, Zix-PG 200/75, Zydol Suspension, and Zixa brand names.
The company provides its products through stockists, doctors, pharmacies, chemists, large government, semi-government institutions, missionary hospitals, public sector enterprises, etc. It exports its products to approximately 13 countries worldwide.
Jenburkt Pharmaceuticals Limited was incorporated in 1985 and is based in Mumbai, India.
| Country | India |
| Founded | 1985 |
| Industry | Pharmaceutical Preparations |
| Employees | 752 |
| CEO | Ashish Bhuta |
Contact Details
Address: Nirmala Apartments Mumbai, Maharashtra 400058 India | |
| Phone | 91 22 6760 3603 |
| Website | jenburkt.com |
Stock Details
| Ticker Symbol | 524731 |
| Exchange | Bombay Stock Exchange |
| Fiscal Year | April - March |
| Reporting Currency | INR |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Ashish Bhuta | Chief Executive Officer |
| Dilip Bhuta | Chief Financial Officer |